NAGE Stock Analysis: Buy, Sell, or Hold?
NAGE - Niagen Bioscience, Inc. Common Stock
$3.22
0.01 (0.31%)
â˛
5d:
+5.92%
30d:
+0.31%
90d:
-12.02%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 04, 2026
0d
Get Alerted When NAGE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: NAGE is fairly priced but lacks strong directional signals. At 21.0% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: NAGE is fairly priced but lacks strong directional signals. At 21.0% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: NAGE is currently trading at $3.22, which is considered fair relative to its 30-day fair value range of $3.07 to $3.41. From a valuation perspective, the stock is trading at a premium (Forward PE: 32.1) compared to its historical average (18.1). At these levels, the market is pricing in 21.0% annual earnings growth.
Technical Outlook: Technically, NAGE is in a strong downtrend. The price is approaching resistance at $3.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.08 (+276.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NAGE is in a strong downtrend. The price is approaching resistance at $3.28. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 50/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $12.08 (+276.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.07 -
$3.41
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.7%
Protect Your Profits
Holding NAGE? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (50/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 276.4% below Wall St target ($12.08)
- BULLISH: Expecting earnings turnaround to 21.0% growth with -4.3% revenue growth
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.07 -
$3.41
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.96
Resistance Level
$3.28
Current Trend
Strong Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
32.10
Wall Street Target
$12.08
(+276.4%)
Revenue Growth (YoY)
-4.3%
Earnings Growth (YoY)
-75.0%
Profit Margin
12.4%
Valuation Premium vs History
+21.0% premium
PE vs Historical
32.1 vs 18.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+21.0%
(market-implied from PE analysis)
1-Year Target
$3.88
(+21%)
2-Year Target
$4.70
(+46%)
3-Year Target
$5.69
(+77%)
3-Yr Target (if PE normalizes)
(PE: 32â18)
PE COMPRESSION
$3.21
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 32.1, Growth: 11.1%)
$4.40
(+37%)
Base:
(SPY PE: 20.1, Growth: 11.1%)
$2.75
(-14%)
Bear:
(PE: 17.1, Growth: 11.1%)
$2.34
(-27%)
đ
Valuation based on Current Earnings
Trailing PE: 16.58 | Current EPS (TTM): $0.19
Bull Case
$1.82
(-43%)
Analyst growth -47.4%, PE expands to 18.2
Base Case
$1.66
(-48%)
Market implied -47.4%, PE stable at 16.6
Bear Case
$2.14
(-33%)
Severe decline -20.0%, PE contracts to 14.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 24, 2026 3:26 PM ET
Data refreshes hourly during market hours. Next update: 4:26 PM
Data refreshes hourly during market hours. Next update: 4:26 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAGE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 39 SELL |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 55 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 53 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 46 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 45 HOLD |
Advanced NAGE Option Strategies
Professional options setups generated by AI based on today's NAGE price and gamma walls.
